Drugs /

samuraciclib

Back to Drugs List

Overview

NCI Definition [1]:
An orally available, selective inhibitor of cyclin-dependent kinase 7 (CDK7) with potential antineoplastic activity. Upon oral administration, samuraciclib selectively and competitively binds to the CDK7 ATP binding site, thereby inhibiting CDK7-mediated signaling. CDK7, a serine/threonine kinase, plays a role in controlling cell cycle progression, transcriptional regulation, and promotes the expression of key oncogenes such as c-Myc through the phosphorylation of RNA polymerase II. Inhibition of CDK7 may inhibit tumor cell proliferation in certain cancers that are dependent on CDK7-mediated transcriptional regulation and signaling.

Clinical Trials

View Clinical Trials for samuraciclib

Samuraciclib has been investigated in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial investigating samuraciclib, 1 is phase 1/phase 2 (1 open).

ER Expression, ER Negative, and ER No Expression are the most frequent biomarker inclusion criteria for samuraciclib clinical trials.

Breast carcinoma, malignant solid tumor, and ovarian carcinoma are the most common diseases being investigated in samuraciclib clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Samuraciclib
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating samuraciclib and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
samuraciclib, icec0942, ct7001, ct-7001, ct 7001, cdk7 inhibitor ct7001
Drug Target(s) [2]:
CDK7
NCIT ID [1]:
C155652

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.